登录 | 注册    关注公众号  
微信公众号
搜索
>产品&服务 > 补体系统,先天免疫“加油站”

补体系统,先天免疫“加油站”

补体系统
背景
补体系统是先天免疫防御的重要组成部分。它不仅有助于局部炎症、去除和杀死病原体,而且有助于形成适应性免疫反应。同时,补体在早期危险传感器中占据独特位置,可直接作用于触发细胞或物质表面,并作为下游细胞和体液免疫反应的协调器,使补体成为一个有趣的药理学靶点。抑制或重塑补体反应可以在疾病进一步传播之前预防大部分疾病驱动的损伤,并且可能比阻断单个细胞因子或其他后期介质更有效。近年来,对补体激活机制、结构、功能方面取得了显著进展,为补体生物学增添了新的复杂性。这种复杂性反映在广泛的炎症、神经退行性疾病和癌症中,补体以网络形式影响免疫和疾病发病机制。
补体级联中药物干预的目标及其相关抑制剂

补体级联中药物干预的目标及其相关抑制剂

http://dx.doi.org/10.1016/j.smim.2016.06.001

补体系统是一种古老的蛋白质级联,具有多种不同功能:调理、趋化和裂解等。补体级联可以通过三种不同的途径激活:经典途径(CP)、凝集素途径(LP)和替代途径(AP)以实现选择性地识别外来病原体和受损的自身细胞。补体靶向治疗在过去几年中已经发展成为一个非常活跃的领域。强效补体抑制剂目前已上市,并越来越多地用于已批准和标示外的适应症,这些适应症证明了控制补体的治疗潜力。因此,在级联水平上进行干预的补体靶向药物将有助于更好地调整治疗策略,并使这种策略应用于更广泛的适应症。
补体激活及其相关疾病

补体激活及其相关疾病

抗补体药物及其临床进展

抗补体药物及其临床进展

https://doi.org/10.1016/j.molimm.2019.07.030

更加充分了解补体的结构、功能和生物学作用将支持我们基于补体的认识为治疗炎症、神经退行性疾病、癌症和COVID-19做出贡献。ACROBiosystems百普赛斯开发了一系列HEK293表达的补体蛋白,包括 C2C3C5(包括突变型)C5a补体因子D(CFD),种属覆盖更全面,高纯度经SDS-PAGE验证,均一的确定的结构经MALS验证,高生物活性经ELISA和细胞水平实验验证。
产品特色

产品齐全:全面覆盖热门补体因子靶点

多种属覆盖:人,小鼠,大鼠,食蟹猴...

广泛的应用场景:免疫、抗体筛选及表征等

高生物活性经结合抗体结合验证

严格质控流程,高品质,高批间一致性

免费共享Protocol

产品列表
分子 货号 种属 产品描述 订购/预购
Complement C1s COS-H52H3 Human Human Complement C1s Protein, His Tag

订购

Complement C3 CO3-H82E8 Human Biotinylated Human Complement C3 Protein, His,Avitag™ (MALS verified)

订购

CO3-H52H3 Human Human Complement C3 Protein, His Tag (MALS verified)

订购

CO3-H5253 Human Human Complement component 3 Protein, Fc Tag (MALS verified)

订购

CO3-M52H4 Mouse Mouse Complement C3 Protein, His Tag (MALS verified)

订购

CO3-C52H5 Cynomolgus Cynomolgus Complement C3 Protein, His Tag (MALS verified)

订购

Complement C3a COA-H82Q3 Human Biotinylated Human Complement C3a Protein, His,Avitag™

订购

COA-H5143 Human Human Complement C3a Protein, His Tag

订购

Complement C5 CO5-H82E9 Human Biotinylated Human Complement C5 Protein, His,Avitag™

订购

CO5-H52Hx Human Human Complement C5 (R885H) Protein, His Tag

订购

CO5-H52Ha Human Human Complement C5 Protein, His Tag

订购

CO5-H52H7 Human Human Complement C5 (w917s) Protein, His Tag

订购

CO5-H5253 Human Human Complement C5 Protein, Fc Tag

订购

CO5-M52H4 Mouse Mouse Complement C5 Protein, His Tag

订购

CO5-C52Hx Cynomolgus Cynomolgus Complement C5 Protein, His Tag

订购

CO5-R52H5 Rat Rat Complement C5 Protein, His Tag

订购

CO5-R52H4 Rabbit Rabbit Complement C5 Protein, His Tag

订购

Complement C5a C5A-H525a Human Human Complement C5a Protein, Fc Tag (MALS verified)

订购

C5A-H51H9 Human Human Complement C5a Protein, His Tag

订购

C5A-H5116 Human Human Complement C5a Protein, Tag Free

订购

C5A-M51H4 Mouse Mouse Complement C5a Protein, His Tag

订购

C5A-C51H9 Cynomolgus Cynomolgus Complement C5a Protein, His Tag

订购

C5A-C5118 Cynomolgus Cynomolgus Complement C5a Protein, Tag Free

订购

Complement Factor D CFD-H52H8 Human Human Complement Factor D / CFD Protein, His Tag (active enzyme)

订购

CFD-H5256 Human Human Complement Factor D / CFD Protein, Fc Tag

订购

CFD-R52H3 Rhesus macaque / Cynomolgus Rhesus macaque / Cynomolgus Complement Factor D / CFD Protein, His Tag (active enzyme)

订购

CFD-R5255 Rhesus macaque Rhesus macaque Complement Factor D / CFD Protein, Fc Tag

订购

验证数据
高纯度和高结构均一性经SDS-PAGE和MALS验证
高纯度和高结构均一性经SDS-PAGE和MALS验证

The purity of Human Complement C5a, Fc Tag (Cat. No. C5A-H525a) is more than 90% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.

高纯度和高结构均一性经SDS-PAGE和MALS验证

The purity of Cynomolgus Complement C3, His Tag (Cat. No. CO3-C52H5) is more than 95% and the molecular weight of this protein is around 168-205 kDa verified by SEC-MALS.

高生物活性经抗体结合验证
高生物活性经抗体结合验证

Immobilized Human Complement C5, His Tag (Cat. No. CO5-H52Ha) at 2 μg/mL (100 μL/well) can bind Eculizumab Biosimilar with a linear range of 0.1-4 ng/mL (Routinely tested).

申请 Protocol

高生物活性经抗体结合验证

Immobilized Human Complement C5a, His Tag (Cat. No. C5A-H51H9) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-4 ng/ml (QC tested).

申请 Protocol

高生物活性经细胞水平验证
高生物活性经细胞水平验证

Human Complement C5a, Tag Free (Cat. No. C5A-H5116) induce N-acetyl-β-D-glucosaminidase release from differentiated U937 cells. The ED50 for this effect is 0.215-0.323 μg/mL (Routinely tested).

申请 Protocol

相关阅读

> 【靶点聚焦】【靶点新势力】补体,“整体大于部分之和”

参考文献
  • 1. King B C, Blom A M. Intracellular complement: Evidence, definitions, controversies, and solutions[J]. Immunological Reviews, 2023, 313(1): 104-119.
  • 2. Zelek W M, Xie L, Morgan B P, et al. Compendium of current complement therapeutics[J]. Molecular immunology, 2019, 114: 341-352..
  • 3. Lubbers R, Van Essen M F, Van Kooten C, et al. Production of complement components by cells of the immune system[J]. Clinical & Experimental Immunology, 2017, 188(2): 183-194.
  • 4. Ricklin D, Lambris J D. New milestones ahead in complement-targeted therapy[C]//Seminars in immunology. Academic Press, 2016, 28(3): 208-222.
ACRO质量管理体系

消息提示

请输入您的联系方式,再点击提交!

确定